ITeos Therapeutics Shares Gain as Company Seeks Strategic Alternatives

Dow Jones

14 May

By Katherine Hamilton

ITeos Therapeutics shares climbed after the company said it would evaluate strategic alternatives.

The stock rose 16% to $8.01 on Tuesday, putting it on track for its largest percent increase in a year. Shares are up 7% this year.

The biopharmaceutical company, focused on immuno-oncology treatments, will "promptly evaluate a full range of strategic alternatives to unlock the value of our assets," Chief Executive Michel Detheux said Tuesday.

Detheux's statement came as the company said it was ending a trial due to results he called disappointing. The Phase 2 study, sponsored by GSK, didn't meet its secondary endpoint of progression free survival. The trial was testing a combination of the drugs belrestotug and dostarlimab to treat a certain non-small cell lung cancer.

Along with the results, Detheux cited current market conditions as a factor in the strategic alternatives search. He said iTeos is well positioned to pursue opportunities that maximize shareholder value.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

May 13, 2025 14:09 ET (18:09 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535887440"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535887440\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535887440?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 02:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535887440","market":"us","top_or_hot":-1,"title":"ITeos Therapeutics Shares Gain as Company Seeks Strategic Alternatives","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  ITeos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares climbed after the company said it would evaluate strategic alternatives. \n</p>\n<p>\n  The stock rose 16% to $8.01 on Tuesday, putting it on track for its largest percent increase in a year. Shares are up 7% this year. \n</p>\n<p>\n  The biopharmaceutical company, focused on immuno-oncology treatments, will \"promptly evaluate a full range of strategic alternatives to unlock the value of our assets,\" Chief Executive Michel Detheux said Tuesday. \n</p>\n<p>\n  Detheux's statement came as the company said it was ending a trial due to results he called disappointing. The Phase 2 study, sponsored by GSK, didn't meet its secondary endpoint of progression free survival. The trial was testing a combination of the drugs belrestotug and dostarlimab to treat a certain non-small cell lung cancer. \n</p>\n<p>\n  Along with the results, Detheux cited current market conditions as a factor in the strategic alternatives search. He said iTeos is well positioned to pursue opportunities that maximize shareholder value. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2025 14:09 ET (18:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ITeos Therapeutics Shares Gain as Company Seeks Strategic Alternatives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nITeos Therapeutics Shares Gain as Company Seeks Strategic Alternatives\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-05-14 02:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  ITeos <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares climbed after the company said it would evaluate strategic alternatives. \n</p>\n<p>\n  The stock rose 16% to $8.01 on Tuesday, putting it on track for its largest percent increase in a year. Shares are up 7% this year. \n</p>\n<p>\n  The biopharmaceutical company, focused on immuno-oncology treatments, will \"promptly evaluate a full range of strategic alternatives to unlock the value of our assets,\" Chief Executive Michel Detheux said Tuesday. \n</p>\n<p>\n  Detheux's statement came as the company said it was ending a trial due to results he called disappointing. The Phase 2 study, sponsored by GSK, didn't meet its secondary endpoint of progression free survival. The trial was testing a combination of the drugs belrestotug and dostarlimab to treat a certain non-small cell lung cancer. \n</p>\n<p>\n  Along with the results, Detheux cited current market conditions as a factor in the strategic alternatives search. He said iTeos is well positioned to pursue opportunities that maximize shareholder value. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 13, 2025 14:09 ET (18:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2535887440","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535887440","pubTimestamp":1747159740,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ITeos Therapeutics shares climbed after the company said it would evaluate strategic alternatives.The stock rose 16% to $8.01 on Tuesday, putting it on track for its largest percent increase in a year. Shares are up 7% this year.The biopharmaceutical company, focused on immuno-oncology treatments, will \"promptly evaluate a full range of strategic alternatives to unlock the value of our assets,\" Chief Executive Michel Detheux said Tuesday.Detheux's statement came as the company said it was ending a trial due to results he called disappointing. The Phase 2 study, sponsored by GSK, didn't meet its secondary endpoint of progression free survival. The trial was testing a combination of the drugs belrestotug and dostarlimab to treat a certain non-small cell lung cancer.Along with the results, Detheux cited current market conditions as a factor in the strategic alternatives search. He said iTeos is well positioned to pursue opportunities that maximize shareholder value.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"ITeos Therapeutics寻求战略替代方案，股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ITOS":0.9,"LENZ":1},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  ITeos Therapeutics shares climbed after the company said it would evaluate strategic alternatives. \n\n\n  The stock rose 16% to $8.01 on Tuesday, putting it on track for its largest percent increase in a year. Shares are up 7% this year. \n\n\n  The biopharmaceutical company, focused on immuno-oncology treatments, will \"promptly evaluate a full range of strategic alternatives to unlock the value of our assets,\" Chief Executive Michel Detheux said Tuesday. \n\n\n  Detheux's statement came as the company said it was ending a trial due to results he called disappointing. The Phase 2 study, sponsored by GSK, didn't meet its secondary endpoint of progression free survival. The trial was testing a combination of the drugs belrestotug and dostarlimab to treat a certain non-small cell lung cancer. \n\n\n  Along with the results, Detheux cited current market conditions as a factor in the strategic alternatives search. He said iTeos is well positioned to pursue opportunities that maximize shareholder value. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2025 14:09 ET (18:09 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}